RecruitingPhase 3NCT05862337
Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
Studying Adult hepatocellular carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Intervention
- Anlotinib hydrochloride capsules, Penpulimab injection(drug)
- Enrollment
- 480 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2023 – 2026
Study locations (30)
- The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
- Anhui Provincial Hospital, Hefei, Anhui, China
- The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
- Peking Union Medical College Hospital, Beijing, Beijing Municipality, China
- Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing Municipality, China
- Peking University People's Hospital, Beijing, Beijing Municipality, China
- Beijing Friendship hospital of Capital Medical University, Beijing, Beijing Municipality, China
- Beijing YouAn Hospital,Capital Medical University, Beijing, Beijing Municipality, China
- Chongqing University Cancer Hospital, Chongqing, Chongqing Municipality, China
- Chongqing University Three Gorges Hospital, Chongqing, Chongqing Municipality, China
- Mengchao Hepatobiliary Hospital of Fujian Medical, Fuzhou, Fujian, China
- Fujian Cancer Hospital, Fuzhou, Fujian, China
- Gansu Provincial Cancer Hospital, Lanzhou, Gansu, China
- Lanzhou University First Hospital, Lanzhou, Gansu, China
- Lanzhou University Second Hospital, Lanzhou, Gansu, China
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05862337 on ClinicalTrials.govOther trials for Adult hepatocellular carcinoma
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE2NCT07441369Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases CancerFudan University
- RECRUITINGPHASE2NCT07175441Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular CarcinomaRiboscience, LLC.
- RECRUITINGPHASE2NCT07560488Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular CarcinomaTianjin Medical University Cancer Institute and Hospital
- RECRUITINGPHASE2NCT07010497A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular CarcinomaAsan Medical Center
- RECRUITINGPHASE1, PHASE2NCT07291076A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)Bristol-Myers Squibb
- RECRUITINGPHASE1, PHASE2NCT07500220Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCCBeijing Biotech
- RECRUITINGPHASE2NCT07413354Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular CarcinomaTongji Hospital
- RECRUITINGNANCT07365527Sonoporation and Tumor Microenvironment Response in Colorectal Liver MetastasesZealand University Hospital